CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$60.70 USD
-0.49 (-0.80%)
Updated Sep 17, 2025 10:20 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRSP 60.70 -0.49(-0.80%)
Will CRSP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
Vertex Plunges Around 24% in Six Months: How to Play the Stock
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?
Other News for CRSP
50 Day Moving Average Support appears for CRSP after 5.79% move
Cathie Wood Bets on AMD, Bullish, and Figma; Trims Tempus AI, Roku
Cathie Wood Bets on AMD, Figma, Bullish, and Biotech Plays, Trims Tempus AI, Roku
Crossed Above 50 Day Moving Average appears for CRSP after 2.81% move
Is CRSP preparing for a move? Bollinger Band Squeeze shows up after rising 0.66%